Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2020 08:00 ET | Source: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404

- Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous – - Data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly...